Illustrative image – not actual.The Planning Commission has opposed a proposal by the Department of Industrial Policy & Promotion (DIPP) to limit foreign direct investment (FDI) in Pharma.
The lowering of cap to 49% in critical pharma facilities will reverse the general direction in which the overall FDI policy should move. Without imposing a cap on FDI, the government has already tightened the rules to put in place some conditions and ensure that such investment in existing pharmaceutical companies require government approval.
The finance ministry has also strongly opposed DIPP's proposal requiring the backing of department of health and science and technology.
